Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications

    ... to AML among patients with lower-risk MDS (LR-MDS). Lenalidomide is the drug with the most impressive clinical activity in the ... independence and cytogenetic responses. Furthermore, lenalidomide delays progression to AML and prolongs survival among responders. ...

    Research Article last updated 02/21/2017 - 9:34am.

  2. Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?

    ... Lenalidomide induces in patients with myelodysplastic syndrome (MDS) and ... 50%, respectively. It is still unclear, however, how long lenalidomide treatment should be continued and whether or not the drug could ...

    Research Article last updated 06/03/2015 - 1:21pm.

  3. Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence

    ... ( azacitidine , decitabine , or lenalidomide ) timing (≤ 3 vs.>3months from start of TD) on the likelihood ...

    Research Article last updated 09/13/2017 - 8:58am.

  4. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy

    ... in lower-risk myelodysplastic syndromes (MDS). Lenalidomide (LEN) can correct anemia in 25% of MDS patients without ...

    Research Article last updated 02/21/2017 - 9:43am.

  5. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

    ... The impact of lenalidomide treatment on long-term outcomes of patients with lower risk ... multivariate methodology to analyse the influence of lenalidomide therapy on overall survival (OS) and acute myeloblastic leukaemia ...

    Research Article last updated 07/29/2014 - 12:11pm.

  6. Top honor goes to AAMDSIF Medical Advisor

    ... His laboratory discovered the molecular basis of lenalidomide activity in MDS as well as multiple myeloma. Recent studies ...

    Article last updated 08/29/2017 - 7:54am.

  7. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis

    ... BACKGROUND: Lenalidomide could effectively induce red blood cell (RBC) ... syndrome (MDS) with or without 5q deletion. However whether lenalidomide ultimately improves the overall survival (OS) of lower-risk MDS ...

    Research Article last updated 11/28/2016 - 9:36am.

  8. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    ... double-blind study assessed the efficacy and safety of lenalidomide in 205 RBC transfusion-dependent patients with IPSS ... myelodysplastic syndromes (MDS). Patients received lenalidomide 10 mg/day days 1-21 (n = 69) or 5 mg/day days 1-28 (n = 69) of ...

    Research Article last updated 07/28/2014 - 9:04am.

  9. Lenalidomide performance in the real world: Patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.

    ... BACKGROUND: Lenalidomide is approved for the treatment of anemia with ... death. Claims were used to determine time to initiation of lenalidomide, daily dose, duration, and other MDS therapies. Transfusion status ...

    Research Article last updated 08/15/2013 - 9:50am.

  10. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

    ... Lenalidomide is an effective drug in low-risk myelodysplastic syndromes ... on treatment response and disease progression in 52 lenalidomide-treated patients with del(5q) MDS, conventional G-banding ...

    Research Article last updated 07/29/2014 - 8:58am.